IP Library Patent Application 18939379
Patent Application
App. No. 18/939,379

SALBUTAMOL DELIVERY COMPOSITIONS, DEVICES AND METHODS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/939,379
Abstract

Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a carrier and at least one medicinally active compound, said carrier comprising at least 1234ze(E) and ethanol.

Claims (39)

1 . A pharmaceutical composition comprising:

a. fine particles of salbutamol;

b. from greater than 95% by weight to less than about 98% by weight of HFO-1234ze(E); and

c. from greater than 2% by weight to less than 5% by weight of ethanol.

2 . The pharmaceutical composition of claim 1 consisting essentially of:

a. said fine particles of salbutamol;

b. said HFO-1234ze(E); and

c. said ethanol.

3 . The pharmaceutical composition of claim 2 further comprising from greater than 0.005% by weight to less than 0.015% by weight of oleic acid.

4 . The pharmaceutical composition of claim 1 wherein said fine particles of salbutamol comprise fine particles of salbutamol sulfate.

5 . The pharmaceutical composition of claim 1 wherein said fine particles of salbutamol consist essentially of fine particles of salbutamol sulfate.

6 . The pharmaceutical composition of claim 1 wherein said fine particles of salbutamol consist of fine particles of salbutamol sulfate.

7 . The pharmaceutical composition of claim 1 wherein said salbutamol is present in an amount of from about 2.5 mg/mL to less than about 4.5 mg/mL.

8 . The pharmaceutical composition of claim 7 wherein said salbutamol is present in an amount of from about 2.5 mg/mL to about 3.5 mg/mL.

9 . An aerosol comprising the pharmaceutical composition of claim 1 .

10 . The aerosol of claim 9 wherein the amount of said salbutamol in said aerosol is from about greater than 150 micrograms to about 300 micrograms.

11 . The pharmaceutical composition of claim 1 wherein said HFO-1234ze(E) is present in an amount off from greater than 96% by weight to less than about 98% by weight and said ethanol is present in an amount of from greater than 2% by weight to less than 4% by weight of ethanol.

12 . A pharmaceutical composition comprising:

a. from about 2.5 mg/mL to less than about 4.5 mg/mL of fine particles salbutamol sulfate;

b. a carrier in which said salbutamol sulfate is suspended, said carrier comprising: (i) from about 95% by weight to less than 99% by weight of HFO-1234ze(E); and (ii) from greater than 1% by weight to about 5% by weight of ethanol.

13 . The pharmaceutical composition of claim 12 consisting essentially of:

said salbutamol sulfate particles;

said HFO-1234ze(E); and

said ethanol.

14 . The pharmaceutical composition of claim 12 further comprising from greater than 0.005% by weight to less than 0.015% by weight of oleic acid.

15 . The pharmaceutical composition of claim 14 further comprising from greater than 0.005% by weight to about 0.01% by weight of oleic acid.

16 . A pharmaceutical composition in the form of an aerosol comprising:

a. fine particles of salbutamol sulfate; and

b. a carrier for said fine particulate salbutamol sulfate, said carrier comprising: (i) from about 94% by weight to less than 99% by weight of HFO-1234ze(E); (ii) from greater than 1% by weight to about 6% by weight of ethanol, wherein the amount of said salbutamol sulfate in said aerosol is from about greater than 150 micrograms to about 300 micrograms.

17 . The pharmaceutical composition of claim 15 further comprising oleic acid.

18 . A method for delivering a prescribed dose of salbutamol sulfate comprising:

a. providing in an MDI comprising an actuator and a pharmaceutical composition comprising: (1) a carrier comprising from greater than about 95% by weight to less than 99% by weight of HFO-1234ze(E); and (ii) from greater than 1% by weight to about 5% by weight of ethanol; and (2) fine particles of salbutamol sulfate; and

b. actuating said MDI once to produce a single aerosol spray of said salbutamol sulfate, wherein said single spray contains the prescribed dose of said salbutamol sulfate.

19 . The method of claim 17 wherein said single spray contains said prescribed dose of said salbutamol sulfate, wherein said prescribed dose is an amount of from about 150 micrograms to about 300 micrograms.

20 . The method of claim 17 wherein said aerosol spray consists essentially of:

a. said salbutamol sulfate;

b. said HFO-1234ze(E);

c. said ethanol; and

d. from greater than 0.005% by weight to less than 0.015% by weight of oleic acid.

Assignments (2)
SECURITY INTEREST Recorded Jan 12, 2026
From: SOLSTICE ADVANCED MATERIALS US, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 074569/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2024
From: BOLDT, ERIK; SMITH, GREGORY
To: HONEYWELL INTERNATIONAL INC.
Reel/Frame 069161/0406 →